Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10859795 | 0.79 | MAPT (0.64) | MAPTGAAKDM4EALDH1A1KMT2A | |
| SCHEMBL20599894 | 0.79 | KCNA5 (0.42) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL20600156 | 0.77 | RXFP1 (0.41) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL10726134 | 0.75 | MAPT (0.49) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL445461 | 0.75 | SMN1; SMN2 (0.61) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL1721544 | 0.74 | SMN1; SMN2 (0.65) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL11129959 | 0.73 | LMNA (0.37) | MAPTGAAKDM4ERAB9ANPC1 | |
| SCHEMBL30117873 | 0.72 | RAB9A (0.79) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3096372 | 0.72 | RAB9A (0.79) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11768825 | 0.72 | MAPT (0.47) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866435-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4292650-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116514715-A | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-108699001-B | Heterocyclic compounds as immunomodulators | 因赛特公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230100875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-03-30 | — | — | US | disclosed |
| US-11535615-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-3828171-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20200407357-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| EP-3394033-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3394033-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112730-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174679-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407357-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885GAA 2040/4885KDM4E 3674/4885 |
| US-20230100875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885GAA 2040/4885KDM4E 3674/4885 |
| US-11535615-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPT 4651/4885GAA 2040/4885KDM4E 3674/4885 |
| US-20170174679-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4651/4885GAA 2040/4885KDM4E 3674/4885 |
| US-11866435-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPT 4651/4885GAA 2040/4885KDM4E 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.